Evaluation of Liraglutide 3.0mg in Patients With Poor Weight-loss and a Suboptimal Glucagon-like Peptide-1 Response

NCT03341429 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Obesity

Interventions

DRUG: Liraglutide Pen Injector [Saxenda]
DRUG: Placebo

Sponsor

University College, London